JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.